Article
Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Future oncology (London, England) - 1 Jan 2015
Martin-Liberal Juan, Larkin James
Abstract excerpt
Vemurafenib was the first selective BRAF inhibitor licensed in cancer. It is indicated for the treatment of patients affected by advanced melanoma with BRAF V600 mutation. It has shown successful results in terms of efficacy together with a favorable toxicity profile. Other compounds such as the BRAF inhibitor dabrafenib and the immunotherapeutic agent ipilimumab are also approved in the same group of patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.